Actinogen Medical Limited ACW
ASX · Australia · Health Technology
AUD 0.0550-0.00 (-1.79%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Actinogen Medical CFO Will Souter talked with Proactive about the completion of the final patient visit in the company’s pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial and what investors can expect ahead of top-line results in November. Souter described the final patient visit as “a major milestone in any clinical trial”, noting that XanaMIA has progressed through an interim analysis and three meetings of its independent data monitoring committee. He also highlighted the significant time and effort involved in running the study, with patients undergoing treatment for 36 months. Looking a
This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36-week treatment periodSYDNEY, Australia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that, following the final participant visit on 22 September in the USA, topline results for the XanaMIA phase 2b/3 Alzheimer’s disease (AD) clinical tria
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial, keeping topline results from the closely watched study on track for release in November. The final participant visit took place in the United States,...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.